Abstract
BackgroundThe repression or downregulation of programmed death-ligand 1 (PD-L1) can release its inhibition of T cells and activate antitumor immune responses. Although PD-1 and PD-L1 antibodies are promising treatments for...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have